Ingenol mebutate

  • (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-Dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclpropa[e]annulen-6-yl (2Z )-2- methylbut -2 -enoate
  • 3- Angeloylingenol
  • Ingenol 3- Angelat
  • I3A
  • PEP005

D06BX02

Amorphous substance

Antineoplastic

Template: Infobox chemical / molecular formula search available

Ingenolmebutat is one in the garden spurge (Euphorbia peplus ) occurring substance from the chemical group of diterpenes. It is used as a drug for the topical treatment of actinic keratosis, a disease caused by intense exposure to UV radiation and precancerous skin condition. In the U.S., a ingenolmebutathaltiges gel is approved since January 2012 and in the EU countries since November 2012.

Ingenolmebutat one of the esters of a group of diterpenes ( ingenanes, Tigliane, daphnanes ), which play an important role in the etiology of tumor development.

Early benefit assessment

In Germany ( AMNOG ) must undergo a "benefit assessment " by the Federal Joint Committee (G -BA) since 2011 newly approved drugs with new active substances due to § 35a SGB V when the pharmaceutical company a higher selling price than would achieve the fixed amount. Only if there is an additional benefit compared to an established therapy, the pharmaceutical company can negotiate a price with the central association of statutory health insurance. This also applies to Ingenolmebutat. A first negative evaluation by the Institute for Quality and Efficiency in Health Care ( IQWiG) has taken place. A final decision on the added value of Ingenolmebutat made ​​by the G -BA.

Trade name

Picato (U.S., EU )

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System Philipp Rösler
13334
de